Which thyroid cancer patients need periodic stimulation tests?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 4, 2007, Pages 541-546

  Zanotti Fregonara, Paolo ^a   Khoury, Alexandre ^a   Duron, Françoise ^a   Keller, Isabelle ^a   Christin Maître, Sophie ^a   Kiffel, Thierry ^a   Toubert, Marie Elisabeth ^b   Devaux, Jean Yves ^a   Hindié, Elif ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

131I whole body scintigraphy; rhTSH; Thyroglobulin; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; THYROID CANCER; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME;

EID: 33947209465     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0279-z     Document Type: Article

References (22)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
2. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84.
3. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartosky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
4. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
5. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-57.
6. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005;15:267-73.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
8. Hindie E, Melliere D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974-81.
9. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grabe SKG. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-74.
10. Preissner CM, Nguyen HT, Pomeroy MR, et al. Evaluation of thyroglobulin reagents modified to reduce heterophile antibody interference on Beckman Coulter's Access Immunoassay systems. Presented at the AACC 2004 meeting (presentation number: C-10 AACC).
11. Giovanella L, Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med 2002;40:480-4.
12. Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861-5.
13. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-8.
14. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
15. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7.
16. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74.
17. Ladenson PW, Braverman LE, Mazzaferri EL, Bruker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
18. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Shermen SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85.
19. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
20. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501.
21. Rouxel A, Hejblum G, Bernier MO, Boëlle PY, Ménégaux F, Mansour G, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5362-8.
22. Baudin E, Do Cao C, Cailleux AF, Leboulleuxs S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11.